Precision BioSciences Q3 Loss Narrows to $7.6M on Warrant Gain; Cash Runway Through 2028
DTIL has more than doubled off its 52-week low of $3.53.
Summary
Precision BioSciences' Q3 net loss narrowed to $7.6M from $21.8M on a $12.7M non-cash warrant remeasurement gain, with $108.0M of cash and management-guided runway through 2028.
Key Events · Earnings and Guidance · DTIL
-
Q3 Loss Narrows on Non-Cash Warrant Gain
Net loss was $7.6M versus $21.8M a year ago, driven by a $12.7M non-cash gain on warrant liability remeasurement; the operating loss was roughly flat at $20.4M versus $20.7M.
-
Cash Runway Extended Through 2028
Cash, cash equivalents and restricted cash totaled $108.0M at September 30, 2026, which management says funds operations and the PBGENE-HBV and PBGENE-DMD data milestones through 2028.
-
ATM Funds the Quarter
The company sold 1,408,833 shares through its ATM for $10.9M of net proceeds in Q3 2026, and $10.9M for the nine months, continuing dilution-based funding.
-
Nine-Month Revenue Jumps to $10.8M
Revenue rose to $10.8M from $0.1M a year ago, driven by $6.8M recognized under the TG Therapeutics license milestone and $4.0M from a legacy agriculture license.
Analysis · DTIL · Life Sciences
The headline improvement is accounting, not operating: a $12.7M non-cash gain on warrant liability remeasurement cut the Q3 net loss to $7.6M from $21.8M a year ago, while the operating loss was essentially flat at $20.4M. What matters for the thesis is the balance sheet — $108.0M of cash, cash equivalents and restricted cash, with management stating runway through 2028, which covers the PBGENE-HBV and PBGENE-DMD clinical data milestones. The company is still funding itself through the ATM ($10.9M raised in Q3) and carries a $22.5M Banc of California term loan secured by a cash account that must hold at least the outstanding principal.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DTIL was trading at $7.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.8M. The 52-week trading range was $3.53 to $9.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.